191 related articles for article (PubMed ID: 16137573)
1. L-arginine improves dystrophic phenotype in mdx mice.
Voisin V; Sébrié C; Matecki S; Yu H; Gillet B; Ramonatxo M; Israël M; De la Porte S
Neurobiol Dis; 2005 Oct; 20(1):123-30. PubMed ID: 16137573
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of L-arginine benefits mdx skeletal muscle function.
Barton ER; Morris L; Kawana M; Bish LT; Toursel T
Muscle Nerve; 2005 Dec; 32(6):751-60. PubMed ID: 16116642
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
[TBL] [Abstract][Full Text] [Related]
4. CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy.
Ségalat L; Grisoni K; Archer J; Vargas C; Bertrand A; Anderson JE
Exp Cell Res; 2005 Jan; 302(2):170-9. PubMed ID: 15561099
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice.
Chakkalakal JV; Harrison MA; Carbonetto S; Chin E; Michel RN; Jasmin BJ
Hum Mol Genet; 2004 Feb; 13(4):379-88. PubMed ID: 14681302
[TBL] [Abstract][Full Text] [Related]
7. Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models.
Vianello S; Consolaro F; Bich C; Cancela JM; Roulot M; Lanchec E; Touboul D; Brunelle A; Israël M; Benoit E; de la Porte S
FASEB J; 2014 Jun; 28(6):2603-19. PubMed ID: 24604079
[TBL] [Abstract][Full Text] [Related]
8. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.
Tidball JG; Wehling-Henricks M
Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129
[TBL] [Abstract][Full Text] [Related]
9. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
[TBL] [Abstract][Full Text] [Related]
10. Disodium cromoglycate protects dystrophin-deficient muscle fibers from leakiness.
Marques MJ; Ventura Machado R; Minatel E; Santo Neto H
Muscle Nerve; 2008 Jan; 37(1):61-7. PubMed ID: 17724738
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability.
Matsumura CY; Pertille A; Albuquerque TC; Santo Neto H; Marques MJ
Muscle Nerve; 2009 Feb; 39(2):167-76. PubMed ID: 19145649
[TBL] [Abstract][Full Text] [Related]
12. Evolution of pathological changes in the gastrocnemius of the mdx mice correlate with utrophin and beta-dystroglycan expression.
Roma J; Munell F; Fargas A; Roig M
Acta Neuropathol; 2004 Nov; 108(5):443-52. PubMed ID: 15365724
[TBL] [Abstract][Full Text] [Related]
13. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
[TBL] [Abstract][Full Text] [Related]
14. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice.
Hnia K; Hugon G; Rivier F; Masmoudi A; Mercier J; Mornet D
Am J Pathol; 2007 Feb; 170(2):633-43. PubMed ID: 17255331
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
[TBL] [Abstract][Full Text] [Related]
16. Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene.
Gaedigk R; Law DJ; Fitzgerald-Gustafson KM; McNulty SG; Nsumu NN; Modrcin AC; Rinaldi RJ; Pinson D; Fowler SC; Bilgen M; Burns J; Hauschka SD; White RA
Neuromuscul Disord; 2006 Mar; 16(3):192-203. PubMed ID: 16487708
[TBL] [Abstract][Full Text] [Related]
17. Eicosapentaenoic acid decreases TNF-α and protects dystrophic muscles of mdx mice from degeneration.
Machado RV; Mauricio AF; Taniguti AP; Ferretti R; Neto HS; Marques MJ
J Neuroimmunol; 2011 Mar; 232(1-2):145-50. PubMed ID: 21131061
[TBL] [Abstract][Full Text] [Related]
18. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort.
Archer JD; Vargas CC; Anderson JE
FASEB J; 2006 Apr; 20(6):738-40. PubMed ID: 16464957
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle.
Chakkalakal JV; Michel SA; Chin ER; Michel RN; Jasmin BJ
Hum Mol Genet; 2006 May; 15(9):1423-35. PubMed ID: 16551657
[TBL] [Abstract][Full Text] [Related]
20. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
Hodgetts S; Radley H; Davies M; Grounds MD
Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
